- $50Bn+ Global market opportunity
- Proven concept. Pre-Clinical work completed at PHE, Porton Down
- New Vaccine development and production in minimal timeframe
- Only 100 litres of virus culture estimated per 100m people, opposed to 10 million litres
- Safer – negligible side effects or reactions
- Greater efficacy
- Overcomes the needle phobia of > 700 million people worldwide
- Level up developing and LMI Countries
Delivering a revolution in vaccines